Predicting cancer recurrence and treatment benefits for early-stage lung cancer patients
Accurate prognosis and prediction of clinical benefits of adjuvant therapy for early-stage non-small cell lung cancer
This study is working on a new test that looks at 7 specific genes to help predict if early-stage lung cancer might come back after surgery and to see if extra chemotherapy could be helpful for patients who have had surgery for stage 1 non-small cell lung cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sostos LLC NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10821728 on NIH RePORTER |
What this research studies
This research focuses on developing a new test that uses a 7-gene assay to predict the likelihood of cancer recurrence and the effectiveness of chemotherapy for patients with early-stage non-small cell lung cancer (NSCLC) who have had surgery. By utilizing advanced artificial intelligence methods and analyzing genetic information from patients, the study aims to provide more accurate prognoses and treatment recommendations. Patients who have undergone surgery for stage 1 NSCLC without high-risk features will be the primary focus, as the test seeks to identify those at higher risk for recurrence and determine the potential benefits of additional chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone surgical resection for stage 1 non-small cell lung cancer without high-risk features.
Not a fit: Patients with advanced-stage lung cancer or those who have not undergone surgical resection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for early-stage lung cancer patients, improving their chances of survival and quality of life.
How similar studies have performed: Previous studies have shown promising results using similar genetic and AI-based approaches to predict cancer outcomes, indicating potential for success in this research.
Where this research is happening
Morgantown, United States
- Sostos LLC — Morgantown, United States (Active)
Researchers
- Principal investigator: Ye, Qing — Sostos LLC
- Study coordinator: Ye, Qing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.